Navigation Links
Takeda presenta la richiesta di autorizzazione all'immissione in commercio nell'Unione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Date:3/8/2013

Osaka, Giappone, March 8, 2013 /PRNewswire/ --

Takeda Pharmaceutical Company Limited ("Takeda") ha annunciato oggi di aver presentato una richiesta di Autorizzazione all'Immissione in Commercio (AIC) all'Agenzia europea per i medicinali (EMA - European Medicines Agency) per il vedolizumab, un anticorpo monoclonale umanizzato a selettività intestinale in fase sperimentale, destinato al trattamento della malattia di Crohn (MC) e della colite ulcerosa (CU) moderata-grave, le due  malattie infiammatorie intestinali croniche (MICI) più comuni. Se approvato, il vedolizumab potrebbe rappresentare il primo e unico agente biologico a selettività intestinale attualmente sul mercato per le MICI.

"La colite ulcerosa e la malattia di Crohn sono due malattie croniche debilitanti, con notevoli esigenze mediche insoddisfatte, che colpiscono sovente soggetti giovani, nel fiore degli anni", ha dichiarato Asit Parikh , MD, Ph.D, Vice President, General Medicine di Takeda. "Ci incoraggiano i risultati di GEMINI, il programma di sviluppo clinico di fase 3 del vedolizumab, che ha coinvolto circa 3.000 pazienti in quasi 40 Paesi, accreditandosi come il più esteso programma di trial clinico rivolto alle MICI finora realizzato."

In tutto il mondo, sono quasi quattro milioni i pazienti affetti da MICI. Di questi, nell'Unione Europea, più di 500.000 sono affetti da CU e quasi 230.000 da MC. La malattia di Crohn e la colite ulcerosa sono malattie croniche, che determinano l'infiammazione della mucosa del tratto digerente. Mentre lo stato infiammatorio prodotto dalla MC può coinvolgere aree diverse del tratto digerente, la CU colpisce esclusivamente il colon-retto. MC e CU possono essere dolorose e debilitanti, generare complicanze gravi e incidere significativamente sulla qualità di vita dei pazienti.

La presentazione dell'AIC è stata supportata dai risultati degl
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
2. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
3. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
4. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
5. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
6. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
7. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
8. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
9. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
10. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
11. Boston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... 2015 market research with 2020 forecasts as well ... healthcare and medical devices intelligence collection of its ... simulation market with 2020 forecasts spread across 164 ... with 170 tables and figures is now available ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... Aug. 3, 2015 OmniSeq, LLC today ... to the OmniSeq SM Genomic Network.  Recently, ... Institute (RPCI) and announced it was making available ... physician-driven, collaborative approach to genomic diagnostics that provides ... Institute is a rapidly expanding, multidisciplinary cancer care ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Jan. 10, 2011 CoreLab Partners, Inc , ... Inc and Medifacts International, has launched a new advanced ... are pleased to announce the release of our proprietary ... development continuum by offering sponsors advanced technologies and integrated ...
... Underwriters Laboratories (UL), a world ... release of a white paper that addresses the current ... equipment. The white paper, "Home Healthcare Equipment: An ... highlights the unique challenges for manufacturers with the U.S. ...
Cached Medicine Technology:CoreLab Partners Launches Advanced Imaging Application 2CoreLab Partners Launches Advanced Imaging Application 3UL White Paper Examines Key Implications of Growing Home Healthcare Industry 2
(Date:8/3/2015)... ... 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing ... Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien ... Company’s presentation may be accessed via the investor relations section of the Company’s website. ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Dignity Health ... Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The new ... this year in the West Valley. , “Dr. Baldwin is an excellent leader ...
(Date:8/3/2015)... ... ... Foot and Ankle Specialists of the Mid-Atlantic (FASMA) is proud ... in the Mid-Atlantic region – and the second largest in the United States – ... Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew up in Laurel, Maryland. She ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical Association ... once in their lives. Often time, low back and sciatic pain can happen as ... be managed clinically with powerful pain medication or spinal surgery. Dynamic Health Care ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2
... situation in case of an outbreak of bird flu pandemic ... They are asked to appoint a bird flu tsar. A ... to look harder at immediate practical measures and implement it ... said that their problem is that the decision-making was too ...
... 30-45 minutes, performed on all weekdays of the week could ... cancer// is the most common form of cancer in females, ... of their life in the Western world. ,Although ... effective treatment, about 20 percent of all women with breast ...
... at Vanderbilt University have found out what it is ... or toddlers age group.// Their finding has revealed that ... , especially with characters they can associate with. ... which type of video best-engaged toddlers. In the first, ...
... The oft exclaimed ailment called economy class syndrome, that is ... may not be due to cabin environment, //as it is ... supports the assessment that clots could form in healthy people, ... blood flow, especially in the legs, which lead to the ...
... a new study it was found that in case ... or above, their mental abilities are on the decline ... New York City at the 21st Annual Scientific Meeting ... study measured blood pressure and cognitive function in 101 ...
... appearing in the American Journal of Respiratory and Critical Care ... had a loss in lung capacity equivalent to what usually ... terror attacks. ,An average loss of 372 milliliters ... lung's capacity. This loss is at least 10 times more ...
Cached Medicine News:Health News:Moderate Exercise, Key To Breast Cancer Prevention 2Health News:Interactive Video, Better Teaching Aid For Toddlers 2Health News:As You Age Check Your BP for It Can Affect Your Mental Ability 2
... Silver Wire Coil and helix provide ... buckling.,Unique Silver Wire Construction eliminates springback ... Tip is designed to provide a ... aesthetic result. ,Trimmable ends ...
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
Medicine Products: